SCHEMBL3145186

SCHEMBL3145186

O=C(c1ccccc1)c1ccccc1NS(=O)(=O)c1ccc(C(=O)N2CCN(CCCN3CCCCC3)CC2)cc1

nearest known ligand 0.67

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
BDKRB1 P46663 7/20 0.67
KCNH2 Q12809 1/20 0.67
L3MBTL1 Q9Y468 1/20 0.54
RXFP1 Q9HBX9 1/20 0.52
DRD2 P14416 1/20 0.48
HTR2A P28223 1/20 0.48
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
SIGMAR1 Q99720 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3153277 0.99 BDKRB1 (0.66) BDKRB1KCNH2L3MBTL1RXFP1DRD2
SCHEMBL3280606 0.86 BDKRB1 (0.62) BDKRB1KCNH2ALDH1A1
SCHEMBL3149723 0.86 BDKRB1 (0.51) BDKRB1KCNH2L3MBTL1RXFP1LMNA
SCHEMBL15103785 0.85 BDKRB1 (0.61) BDKRB1KCNH2L3MBTL1RXFP1ALDH1A1
SCHEMBL3144805 0.85 BDKRB1 (0.50) BDKRB1KCNH2L3MBTL1RXFP1LMNA
SCHEMBL3273902 0.82 BDKRB1 (0.59) BDKRB1KCNH2L3MBTL1ALDH1A1
SCHEMBL5101094 0.80 BDKRB1 (1.00) BDKRB1KCNH2ALDH1A1
SCHEMBL3275545 0.77 BDKRB1 (0.57) BDKRB1KCNH2L3MBTL1ALDH1A1LMNA
SCHEMBL3278506 0.77 BDKRB1 (0.57) BDKRB1KCNH2L3MBTL1ALDH1A1LMNA
SCHEMBL3157696 0.76 CCR2 (0.51) KCNH2L3MBTL1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074083-B1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-06-19 EP claimed
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-03-25 US claimed
EP-2074083-A1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS Richter Gedeon NYRT (HU) 2009-07-01 EP claimed
WO-2008050168-A1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2008-05-02 WO claimed
EP-2074083-B1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-06-19 EP disclosed
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-03-25 US disclosed
US-20090088438-A1 NEW TYROSINE DERIVATIVES AS PPARy MODULATORS LABORATORIOS SALVAT, S.A. (ES) 2009-04-02 US disclosed
US-7423172-B2 Tyrosine derivatives as PPAR-γ-modulators LABORATORIOS SALVAT, S.A. (ES) 2008-09-09 US disclosed
US-20070276043-A1 Tyrosine Derivatives As Ppar-Gamma-Modulators LABORATORIES SALVAT, S.A. (ES) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088438-A1 NEW TYROSINE DERIVATIVES AS PPARy MODULATORS PPARG, PPARD, TYRO3 BDKRB1 112/4885KCNH2 3290/4885L3MBTL1 2432/4885
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, TRPV1 BDKRB1 1/4885KCNH2 80/4885L3MBTL1 3132/4885
US-20070276043-A1 Tyrosine Derivatives As Ppar-Gamma-Modulators PPARG, PPARD, PPARA BDKRB1 147/4885KCNH2 3013/4885L3MBTL1 2322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.